| NCT ID | NCT03826264 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duk-Woo Park, MD |
| Condition | Heart Valve Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2019-06-15 |
| Primary Completion | 2035-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2019-06-15 with a primary completion date of 2035-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry evaluates the long-term outcome of Transcatheter aortic valve replacement (TAVR) in real-world clinical practice.
Eligibility Criteria
Inclusion Criteria: * All patients undergoing TAVR * Informed consent
Contact & Investigator
Alan Ching Yuen Yeung, MD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT03826264 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Heart Valve Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03826264 currently recruiting?
Yes, NCT03826264 is actively recruiting participants. Contact the research team at dwpark@amc.seoul.kr for enrollment information.
Where is the NCT03826264 trial being conducted?
This trial is being conducted at Stanford, United States, Chicago, United States, Hangzhou, China, Bucheon-si, South Korea and 3 additional locations.
Who is sponsoring the NCT03826264 clinical trial?
NCT03826264 is sponsored by Duk-Woo Park, MD. The principal investigator is Alan Ching Yuen Yeung, MD at Stanford University. The trial plans to enroll 10,000 participants.